Why is the IBDX panel better than other existing serological tests, such as ASCA and pANCA?
No other existing marker has the ability to aid in the differentiation of IBD vs. non-IBD. In distinguishing between CD and UC. Glycominds’ IBDX panel has is proven to be superior, providing significantly higher performance, higher sensitivity and higher specificity, whereas the combination of ASCA /pANCA provide ~50-60% positive predictive value Further benefits include: • Over 90% positive prediction value (PPV) for IBD diagnosis when compared with other GI diseases Over 85% PPV for the differentiation between CD and UC.
